We’re on a mission to enable effective therapies to people faster.
A novel approach to research
For the past two decades clinical research has been hindered by outdated processes and technologies leaving millions without treatments.
After struggling to access patients in her own research in rare skin diseases, Dr. Michelle Longmire set out to solve this long-standing challenge in research.
Drawing inspiration from innovation and technological advancements in other industries, Longmire rallied stakeholders, partners, and developers to launch our company, Medable, with the shared vision of radically increasing the number of effective therapies to people each year.
Committed to science. Powered by innovation.
In order to achieve this vision, we needed to amplify the quality, reach, velocity, and cost of research.
Driven by the belief that clinical research can and should be better, we've assembled world-class scientific and product teams to continuously drive evidence-based improvements to the trial experience for all.
The relentless pursuit of progress, together.
Human connection is at the heart of everything we do. We prioritize the personal experience of patients, caregivers, knowing that their knowledge and feedback are essential to improving clinical research. In close partnership with with our network of sites, we continuously improve our platform, because we know that when they win, we all win. By designing products that are more accessible and user-friendly, we can bring life-change treatments to those who need them faster.
Together, with our clients and partners, we continue to work toward our mission and drive clinical research forward for the betterment of all.
Accolades
The latest from Medable
Eliminate clinical trial white space with the right AI strategy
It has become clear that our industry has reachedthe limits of human-only clinical development. As clinical trials have become increasingly complex, the endeavors that people alone can perform are no longer sufficient to generate the momentum needed to address the growing burden of human disease. This has led to longer drug development timelines and significant delays for patients. One large are of lost time is “white space,” definied simply as unproductive time caused by manual, sequential processes and fragmented data systems. Thankfully, a solution lies in agentic AI and its abilities to perform series of tasks.
Not just a tool: How AI agents become trial teammates
Explore how agentic AI is transforming clinical trials by automating routine tasks and boosting team efficiency with real-world, low-risk use cases.
Why cloud-based eCOA software is becoming the industry standard
The landscape of clinical trials is evolving rapidly, and at the forefront of this transformation is eCOA (electronic Clinical Outcome Assessment) software. This technology is streamlining data collection, enhancing patient compliance, and ensuring regulatory adherence like never before.
Medable Named a Leader Amid Growing eCOA Adoption
Everest Group’s 2025 Life Sciences eCOA PEAK Matrix® Assessment highlights Medable eCOA leadership in ease of use, AI innovation, and patient-centered design
.webp)
Medable Launches The Industry’s First Agentic AI Platform and CRA Agent; Removes Bottlenecks in Clinical Development
Agent Studio marks a turning point in clinical research, moving from human-heavy processes to scalable agents that streamline work and accelerate trials
Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing
Medable unveils its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials.